RGT Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.23 |
| 52 Week High | AU$0.90 |
| 52 Week Low | AU$0.10 |
| Beta | 1.05 |
| 11 Month Change | 34.33% |
| 3 Month Change | 28.57% |
| 1 Year Change | -71.88% |
| 33 Year Change | -99.15% |
| 5 Year Change | n/a |
| Change since IPO | -99.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGT | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -8.2% | 1.2% | 1.1% |
| 1Y | -71.9% | 10.8% | 11.5% |
Return vs Industry: RGT underperformed the UK Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: RGT underperformed the UK Market which returned 11.5% over the past year.
Price Volatility
| RGT volatility | |
|---|---|
| RGT Average Weekly Movement | 27.2% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: RGT's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: RGT's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| RGT fundamental statistics | |
|---|---|
| Market cap | UK£9.71m |
| Earnings (TTM) | -UK£9.01m |
| Revenue (TTM) | UK£458.12k |
19.0x
P/S Ratio-1.0x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGT income statement (TTM) | |
|---|---|
| Revenue | AU$891.08k |
| Cost of Revenue | AU$1.20m |
| Gross Profit | -AU$304.15k |
| Other Expenses | AU$17.23m |
| Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -34.13% |
| Net Profit Margin | -1,967.34% |
| Debt/Equity Ratio | -149.0% |
How did RGT perform over the long term?
See historical performance and comparison